You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm also recently validated its instrument-agnostic technology's ability to detect up to 20 targets per qPCR well using high-definition PCR.
The deal covers SpeeDx's ResistancePlus and PlexPCR product lines, which include tests for sexually transmitted infections and antibiotic resistance.
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
The MiQLab system can look for 27 different targets, allowing the detection of SARS-CoV-2 as well as the determination of specific variants.
The company said the study will evaluate the ability of its Reveal System to detect and characterize antimicrobial resistance of Gram-negative bacteremia samples.
Despite the Q4 revenue increase, sales for FY2020 dropped 13 percent year over year to $5.2 million.
During the quarter, the Tucson, Arizona-based company added 45 instruments for a total of 268 revenue-generating instruments installed in the US.
The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.
The European Commission recently awarded the company a two-year, €2.6 million Horizon 2020 grant to achieve its ambitions.
The Mountain View, California-based firm will first offer the system for evaluation and clinical use in France and the United Kingdom.
